News headlines about Rockwell Medical (NASDAQ:RMTI) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Rockwell Medical earned a media sentiment score of 0.08 on Accern’s scale. Accern also gave news stories about the company an impact score of 45.2077062057717 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

A number of research firms have commented on RMTI. BidaskClub raised Rockwell Medical from a “sell” rating to a “hold” rating in a report on Friday, December 15th. Zacks Investment Research raised Rockwell Medical from a “hold” rating to a “buy” rating and set a $7.50 target price for the company in a report on Wednesday, October 25th.

Shares of Rockwell Medical (NASDAQ RMTI) opened at $5.87 on Tuesday. Rockwell Medical has a fifty-two week low of $5.06 and a fifty-two week high of $8.98. The company has a market capitalization of $306.42, a price-to-earnings ratio of -13.65 and a beta of 2.02.

Rockwell Medical (NASDAQ:RMTI) last released its earnings results on Wednesday, November 8th. The company reported ($0.10) EPS for the quarter, meeting analysts’ consensus estimates of ($0.10). Rockwell Medical had a negative return on equity of 46.63% and a negative net margin of 39.28%. The company had revenue of $14.63 million during the quarter, compared to the consensus estimate of $13.33 million. During the same quarter last year, the company earned ($0.09) earnings per share. Rockwell Medical’s quarterly revenue was up 14.2% compared to the same quarter last year. research analysts anticipate that Rockwell Medical will post -0.44 earnings per share for the current fiscal year.

WARNING: This piece was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at

Rockwell Medical Company Profile

Rockwell Medical, Inc (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process.

Insider Buying and Selling by Quarter for Rockwell Medical (NASDAQ:RMTI)

Receive News & Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related companies with's FREE daily email newsletter.